VIVANI MEDICAL, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.33 USD | -6.99% |
|
-17.90% | +30.39% |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 68.72M 93.97M |
|---|---|---|---|---|---|
| Net income 2024 * | -27M -36.92M | Net income 2025 * | -31M -42.39M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-2.5
x | P/E ratio 2025 * |
-2.23
x | Employees | 36 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.46% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -6.99% | ||
| 1 week | -17.90% | ||
| Current month | -18.40% | ||
| 1 month | -27.72% | ||
| 3 months | -33.50% | ||
| 6 months | +51.69% | ||
| Current year | +30.39% |
1 week
1.23
1.60
1 month
1.232.09
Current year
1.007.80
1 year
0.847.80
3 years
0.757.80
5 years
0.757.80
10 years
0.757.80
| Managers | Title | Age | Since |
|---|---|---|---|
Adam Mendelsohn
FOU | Founder | 42 | 03-05-21 |
Brigid Makes
DFI | Director of Finance/CFO | 68 | 22-08-29 |
Truc Le
COO | Chief Operating Officer | 71 | 22-08-29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gregg Williams
CHM | Chairman | 65 | 08-12-31 |
Wilford Baker
BRD | Director/Board Member | 81 | 20-12-31 |
Aaron Mendelsohn
BRD | Director/Board Member | 72 | 97-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-20 | 1.25 | -6.02% | 415,923 |
| 24-06-18 | 1.33 | -6.99% | 380,400 |
| 24-06-17 | 1.43 | -10.63% | 561,827 |
| 24-06-14 | 1.6 | -1.23% | 739,315 |
| 24-06-13 | 1.62 | -0.61% | 14,740,957 |
End-of-day quote Nasdaq, June 17, 2024
More quotes
Vivani Medical, Inc. is a preclinical-stage biopharmaceutical company. The Company develops miniaturized and subdermal implants utilizing its NanoPortal technology to enable the delivery of a range of medicines to treat chronic diseases. It is engaged in the development of the Companyâs lead programs NPM-115 and NPM-119, is a GLP-1 implant candidates for the treatment of chronic weight management and patients with type 2 diabetes, respectively. Its other pipeline product candidates include NPM-139, and OKV-119. It uses this platform technology to develop and commercialize drug implant candidates for the treatment of chronic disease and medication non-adherence. It operates through two segments: Biopharm Division and Neuromodulation Division. The Companyâs implant technology, which it refers as NanoPortal, utilizes a space-efficient design that allows a miniaturized implant to provide many months of therapeutic delivery of potent molecules.
Calendar
2024-06-27
- Annual General Meeting
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.25
USD
Average target price
8
USD
Spread / Average Target
+540.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +30.39% | 68.72M | |
| +13.99% | 130B | |
| -7.37% | 11.04B | |
| -14.32% | 7.46B | |
| +40.47% | 5.62B | |
| -17.56% | 4.98B | |
| +8.18% | 3.43B | |
| -20.46% | 2.44B | |
| -17.89% | 1.92B | |
| -19.16% | 1.79B |
- Stock Market
- Equities
- VANI Stock
